Press Releases
Update: Proposed Delisting from the Official List of ASX – Formal Consent of ASX to Delist – Filing of Final Definitive Proxy Statement and Notice of Special Meeting
BOSTON and SYDNEY — 27 May 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, confirms that further to its announcement of 11 May 2020, the Company has applied to the Australian...
read moreExtension of Maturity Date of 2017 Note and Operational Update
BOSTON and SYDNEY — 4 May 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, provides the following update regarding its operations and financing. Extension of Maturity Date of June...
read moreGI Dynamics Announces Change to Board of Directors
BOSTON and SYDNEY — 30 March 2020 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces today that Timothy Barberich resigned as a non-executive director of its Board of Directors (the Board) effective as of...
read moreAppointment of Director
BOSTON and SYDNEY — 2 March 2020 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has increased the size of the Board from four to five directors and elected Dr. Praveen Tyle, Ph.D....
read moreFirst Patient Enrolled in the US STEP-1 Clinical Trial of EndoBarrier at Michigan Medicine
BOSTON and SYDNEY — 28 January 2020 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the first patient in the United States (U.S.) STEP-1 clinical trial has been enrolled at Michigan...
read moreEndoBarrier Study Shows Improvement in Cardiovascular Risk
BOSTON and SYDNEY — 15 January 2020 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive EndoBarrier data from the University of Freiburg in Germany showing improvements of...
read moreConfirmation of Funding of 2019 Note and Issuance of Warrants
BOSTON and SYDNEY — 14 January 2020 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that further to its announcements of 22 August 2019, 6 December 2019, 9 December 2019 and 17 December...
read more